According to a new study cancer patients with cholangiocarcinoma
(bile duct cancer) with a BRAF V600E mutation can benefit from treatment with two biological drugs included in the melanoma health basket. This is only 5% of all cholangiocarcinoma patients.
These advanced and innovative drugs are Tafinlar® (Dabrafenib) and Mekinist® (Trametinib) of Novartis®
The intermediate results observed in the study were similar to the standard treatment, which is a combination of two chemotherapies, a Gamzer and Cisplatin given as first line treatment for advanced disease. Therefore, this combination is more successful because the patient will not tolerate the severe side effects of chemotherapy and will benefit from biological therapy with far fewer side effects.
The combination of Tafinlar® and Mekinist® is effective not only in cholangiocarcinoma but also in melanoma, lung cancer and anaplastic thyroid cancer.
Do not wait for the condition to get worse – there is hope and we can bring you value as long as you are at the beginning of your coping with the metastatic disease.
TRIAL•IN Pharma provides a unique, personalized service for patients with stage IV metastatic cancer and brain tumors, which reveals innovative and advanced cancer treatments around the world and helps to achieve them.
Call us 24/7 toll free to find out if our services match your current medical and clinical condition:
+44.2082.426.039or leave us a message on our website and we’ll get back to you shortly
TRIAL•IN Pharma – We do not give up on life!
To read more:
https://www.medscape.com/viewarticle/908219…
